New and forthcoming therapies for viral hepatitis

Journal of Hepatology, Supplement

Volumn 24, Issue 2, 1996, Pages 74-76

  Carreno, Vicente ^a,c   Quiroga, Juan Antonio ^b  

^a Fundacion Jiniene Diaz   (Spain)

^b Fimdacion Para el Estudio de Las Hepatitis Virales ^*  (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Therapy; Vital hepatitis B and C

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; RIBOZYME; VIRUS RNA;

BONE MARROW SUPPRESSION; CONFERENCE PAPER; DOSE RESPONSE; DRUG POTENTIATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; LEUKOCYTE COUNT; LIVER CIRRHOSIS; PRIORITY JOURNAL; VIRUS HEPATITIS; VIRUS IMMUNITY; VIRUS REPLICATION;

GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPATITIS B; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2;

EID: 0029739277     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
2. Chisari FV. Hepatitis B virus biology and pathogenesis. Mol Gen Med 1992; 2: 67-104.
3. Gerber MA. Pathobiologic effects of hepatitis C. J Hepatol 1995; 22 (Suppl.l): 83-6.
4. Hoofnagle JH. Interferon therapy of viral hepatitis. In: Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR, Hughes TK, Kumpel GR, Niesel DW, Stanton GJ, Tyring SK, eds. Interferon: Principles and Medical Applications. Galveston: The University of Texas Medical Branch at Galveston, 1992:431-62.
5. Staeheli P. Interferon-induced proteins and the antiviral state. Adv Virus Res 1990; 38: 147-200.
6. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991; 13: 364-75.
7. Lau AS. Cytokines in the pathogenesis and treatment of infectious diseases. Adv Pediatr Infect Dis 1994; 9: 211-36.
8. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (part II). N Engl J Med 1992; 327: 99-106.
9. Bocci V Interleukins. Clinical pharmacokinetics and practical implications. Clin Pharmacokinet 1991; 21: 274-84.
10. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (part I). N Engl J Med 1992; 327: 28-35.
11. Martin J, Bosch O, Moraleda G, Bartolomé J, Quiroga JA, Carreno V. Pilot study of recombinant human granulocytemacrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology 1993; 18: 775-80.
12. Martin J, Quiroga JA, Bosch O, Carreno V. Changes m cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in chronic hepatitis B. Hepatology 1994; 20: 1156-61.
13. Suva M, Ferez V, Manero E, Escoms S, Tanno H, Bariletto S, Albrecht J. GM-CSF plus interferon in chronic hepatitis B patients who failed previous interferon therapy. Hepatology 1994; 20: 300A (Abstr).
14. Carreno V, Parra A, Navas S, Quiroga JA. Granulocytemacrophage colony-stimulating factor as adjuvant therapy for interferon-or treatment of chronic hepatitis C. Cytokine (in press).
15. Gurakar A, Fagiuoli S, Gavaler JS, Hassanein T, Jabbour N, Wright HI, Deal SA, Shah A, Brown M, Carr BI, Van Thiel DH. The use of granulocyte-macrophage colony-stimulating factor to enhance hématologie parameters of patients with cirrhosis and hypersplenism. J Hepatol 1994; 21: 582-6.
16. Hoofnagle JH, Di Bisceglie AM, Waggner JG, Park Y. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 116-21.
17. Perrillo RP. Chronic hepatitis B: problem patients (including patients with decompensated disease). J Hepatol 1995; 22 (Suppl.I):45-8.
18. Van Thiel DH, Faruki H, Fagiuoli S, Friedlander L, Wright HI, Casaceni P, Molloy P, Kania RJ. Successful treatment of end stage liver disease due to hepatitis C prior to liver transplantation. Hepatology 1994; 20: 137A (Abstr).
19. Kitis G, Papagianni E, Tzilves D, Kordits F, Kokozidis G. Co-administration of granulocyte colony-stimulating factor allows completion of interferon therapy in chronic viral hepatitis with neutropenia. Hepatology 1994; 20: 171A (Abstr).
20. Wright HI, Gavaler JS, Van Thiel DH. Granulocyte colonystimulating factor (G-CSF) combined with a-interferon (aIFN) for treatment of liver allograft recipients with viral hepatitis. Hepatology 1991; 14: 48A (Abstr).
21. Pardo M, Castillo I, Navas S, Carreno V Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha. J Med Virol 1995; 45: 439-44.
22. Martin J, Navas S, Quiroga JA, Carreno V Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine (in press).
23. Bruch HR, Korn A, Klein H, Markus R, Malmus K, Baumgarten R, Müller R. Treatment of chronic hepatitis B with interferon a-2b and interleukin-2. J Hepatol 1993; 17 (Suppl.3): 52-5.
24. Carreno V, Artillo S, Bartolomé J, Pastore G, Santantonio T, Milella M, Fattovich G, Giustina G, Albert! A, Chaneac M. A multicenter randomized double-blind placebo-controlled trial of interleukin-2 in chronic hepatitis B. Hepatology 1993; 18: 225A (Abstr).
25. Tilg H, Vogel W, Tratkiewicz J, Aulitzky WE, Herold M, Gruber M, Geissler D, Umlauft F, Judmaier G, Schwulera U, Thrun A, Huber C. Pilot study of natural interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects. J Hepatol 1993; 19: 259-67.
26. Carreno V, Castillo I, Gonzalez A, Pardo M. Interleukin-2 treatment in chronic hepatitis C. Hepatology 1994; 20: 170A (Abstr).
27. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides in an in vitro test system. Hepatology 1995; 22: 707-17.
28. Bartolomé J, Madejön A, Carreno V Ribozymes: structures, characteristics and use as potential antiviral agents. J Hepatol 1995; 22 (Suppl.l): 57-64.
29. Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 1995; 23: 98-101.